Announcements Trials
Browse Landscape

Phase

Phase 1 19Phase 2 16Phase 1/2 10Phase 3 3

Status

Completed 3Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Gastrointestinal 1

Conditions

Skin Neoplasms 2Skin Diseases 2Neoplasm Metastasis 2Melanoma 2Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × binimetinib × Clear all
NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT02928224 2023-12-21

BEACON CRC

Pfizer

Phase 3 Completed
702 enrolled 82 charts 1 FDA
Gastrointestinal

Colorectal Neoplasms

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡